Información del producto
Israpafant is a prodrug that is hydrolyzed to ertapenem, its active form. It inhibits bacterial growth by inhibiting the synthesis of cell wall peptidoglycan. Israpafant also prevents the formation of covalent bonds between lipid molecules and proteins and has been shown to be effective in treating inflammatory bowel disease (IBD). Israpafant is absorbed through the oral cavity, which enhances the absorption of ertapenem into the bloodstream. The absorption enhancer is processed by hydrochloric acid and fatty acids in the stomach cavity before it becomes available for use in other areas of the body. Israpafant has a particle size of less than 1 micron; this small particle size allows for an increased surface area with more exposure to hydroxyl groups which are needed for its activation.
Propiedades químicas
Consulta técnica sobre: 3D-SEA27973 Israpafant
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.
